Company Overview of NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc., a drug discovery company, engages in the identification and development of transformational biologics for the treatment of diabetes, obesity, muscle wasting, and other cardio metabolic diseases. It focuses on mining the complex biological interactions within the neuroendocrine gastrointestinal (GI) environment to elucidate the roles of previously unidentified or unexplored hormones, receptors, and other metabolic factors that are involved in the systemic regulation of glucose homeostasis and that play causative roles in diseases. The company also develops novel therapeutics to modulate beta-cell regeneration for the treatment of Type 1 and Type 2 diabetes. In ad...
630 Gateway Boulevard
South San Francisco, CA 94080-7014
Founded in 2007
Key Executives for NGM Biopharmaceuticals, Inc.
Chief Executive Officer and Director
Vice President of CMC and Technical Operations
Vice President of Business Development
Executive Director of Research Operations
Compensation as of Fiscal Year 2013.
NGM Biopharmaceuticals, Inc. Key Developments
MedImmune and NGM Biopharmaceuticals Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity
Jun 17 13
AstraZeneca announced that MedImmune and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM's enteroendocrine cell (EEC) programme for the treatment of type 2 diabetes and obesity. EECs represent less than 1% of all gastrointestinal (GI) cells, but produce virtually all of the known GI hormones, including GLP-1. EECs are an underexplored source of novel hormones that could play a major role in the positive and negative regulation of metabolism and glucose homeostasis. NGM has established a proprietary platform capable of isolating and analysing EECs in order to identify novel secreted peptide hormones that are potentially linked to the profound metabolic effects of bariatric surgery and serve as potential targets for the treatment of metabolic diseases. MedImmune and NGM will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones. MedImmune will have the option to license in these EEC targets, and will be responsible for the global development, manufacture and commercialisation of compounds resulting from the collaboration. Under the terms of the agreement, MedImmune will make an upfront payment and provide NGM research funding over the course of the collaboration. If certain development, regulatory and commercial milestones are achieved, NGM will be entitled to receive various payments, as well as royalties on worldwide product sales.
NGM Biopharmaceuticals, Inc. Enters Agreement with Janssen Pharmaceuticals, Inc. to Discover and Develop Novel Therapeutics for Diabetes
Jan 3 13
NGM Biopharmaceuticals, Inc. announced that it has signed a worldwide agreement with Janssen Pharmaceuticals, Inc. to discover and develop novel therapeutics for the potential treatment of Type 2 diabetes and other metabolic diseases. NGM and Janssen will jointly conduct research on selected protein factors discovered by NGM using its diabetes discovery platform, with the goal of advancing drug candidates that mimic the potential gluco-regulatory effects of bariatric surgery on diabetes patients. Janssen will receive an exclusive worldwide license to develop, manufacture and commercialize compounds resulting from the collaboration. Under the terms of the agreement, NGM will receive an upfront payment and research support for activities conducted in collaboration with Janssen. In addition, NGM is eligible to receive payments upon the achievement of certain research, development, regulatory and commercial milestones, as well as royalties on worldwide product sales.
Daiichi Sankyo Company, Limited Signs Research Collaboration and License Agreement with NGM Biopharmaceuticals, Inc
Mar 29 12
Daiichi Sankyo Company, Limited has entered into research collaboration and license agreement with NGM Biopharmaceuticals, Inc. to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes. As a part of the agreement, NGM will apply its integrated discovery technology and in vivo screening platform to identify and validate physiologically-relevant metabolic targets that modulate beta-cell growth and function. Daiichi Sankyo and NGM will jointly conduct research on selected targets with the goal of identifying and optimizing drug candidates for further development. Daiichi Sankyo will assume responsibility for preclinical studies, clinical development, manufacturing and commercialization on a worldwide basis. Under the terms of the agreement, NGM will receive an upfront payment and committed research funding for the duration of the agreement. In addition, NGM is eligible to receive payments upon the achievement of research, development, regulatory and commercial milestones, as well as royalties on product sales. Daiichi Sankyo will receive an exclusive worldwide license to develop and commercialize compounds resulting from the agreement.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 9, 2013